“I hope I’m one thing worth not forgetting. Tell me that you’ll never let me go. When I can’t find the words that I’m trying to speak, when I don’t know the face in the mirror I see, when I feel I’m forgotten and lost in this world, won’t you please remember me?”~”Remember Me,” written by Chris Mann and Dr. Rudolph Tanzi along with Laura Mann, Willy Beaman and Dr. Dora Kovacs.
“I believe there is a significant possibility that we will have a solid plan for eradicating Alzheimer’s disease by 2025.”
The statement comes from Dr. Rudolph Tanzi, one of the foremost scientists behind curing the progressive, degenerative brain disease that the Alzheimer’s Association predicts will destroy the memories of some 14 million Americans by 2050.
, Neurogeneticist Dr. Rudolph Tanzi, the vice-chair of Neurology and director of the Genetics and Aging Research Unit at Massachusetts General Hospital. Tanzi, who serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School, co-discovered all three early-onset familial Alzheimer’s disease genes and identified several others as leader of the Alzheimer’s Genome Project.
Hot Medical Stocks To Watch Right Now: Logitech International S.A.(LOGI)
- [By WWW.THESTREET.COM]
For his “Executive Decision” segment, Cramer once again sat down with Bracken Darrell, president and CEO of Logitech (LOGI) , the computer accessory maker with shares that are up 27% since Cramer last checked in back in November.
- [By Lisa Levin]
Mad Catz Interactive, Inc. (USA) (NYSE: MCZ) shares were also up, gaining 35 percent to $0.260 as the company disclosed that it has sold its Saitek simulation product line to Logitech International SA (USA) (NASDAQ: LOGI) for $13 million in cash.
Hot Medical Stocks To Watch Right Now: Radient Technologies (RTI)
- [By Jim Robertson]
Shares of small cap natural compound and Cannabinoid extract stock Radient Technologies (CVE: RTI) have been taking off lately as the Company makes further progress commercializing its technology. The Company extracts natural compounds from a range of biological materials using microwave assisted processing (MAP), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield and cost. This technology is based on the selective and localized heating of the moisture present in all natural materials using microwaves as the energy source. This gives the Company a technological advantage and expertise in selectively depositing microwave energy into different parts of a biomass’ complicated chemical system form the core of our extraction advantage.
- [By Bryan Murphy]
It’s been a long time in the coming, but there’s no denying the tipping point has been reached — cannabinoids are the foundation for a whole new kind of medicine. And, the work-to-date turning cannabis into pharmaceuticals has been very encouraging.
Problem: While the premise of cannabinoids as drugs has been validated, the science of creating large quantities of pure cannabinoids remains more ineffective than effective. Radient Technologies Inc (CVE:RTI) is about the change that, leveraging a means of extracting a lot of cannabinoid material from a source, and ensuring the highest-level of purity and quality.
Radient Technologies manufactures natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics. Using a proprietary, patented technology, Radient’s products are superior in quality and purity while manufactured at a significantly lower cost than other methods thanks to superior yields and efficiency.
To fully appreciate the science Radient has developed, however, one must understand the alternative methods currently employed.
With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated, and then over the course of several hours the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.
It works, but it’s far from ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, many undesirable components can still be found in the extract, lowering the quality and purity of the ingredient.
Radient Technologies uses an ingredient-extraction process called microwave assisted processing, or “MAP,” for short.
Using its patented MAP process, Radient is able to selectiv
- [By Jim Robertson]
Small cap Radient Technologies (CVE: RTI) is focused on extracting, isolating and purifying food/nutraceutical ingredients (colourings, flavourings, preservatives etc) and pharmaceutical raw materials from its20,000 square foot manufacturing plant in Edmonton, Alberta. The Companyworks with global brands across a range of industries (including Food and Beverage, Nutrition and Supplements, Pharmaceuticals, Personal Care and Cosmetics and Biofuel) andengageswithits clients in three distinct phases:
- [By Matthew Briar]
At first glance, a new set of rules from the Drug Enforcement Agency unveiled in the middle of December looked like it posed a problem for cannabis-newcomer Radient Technologies Inc (CVE:RTI). By assigning a controlled substances code number to ‘marijuana extract,’ simultaneously distinguishing (and acknowledging the differences of marijuana, hemp and their derivatives as Schedule I substances. As the ruling’s language explained, “This code number will allow DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana. This, in turn, will aid in complying with relevant treaty provisions.”
It presents something of an uncertainty, as it was not clear of the DEA also meant hemp and cannabis extracts when it used the term ‘marijuana extract.’ After all, the Drug Enforcement Agency has thus far done a poor job of distinguishing between hemp and marijuana, but has generally erred on the side of grouping everything as marijuana…. even if it didn’t cause a ‘high,’ and even if it did provide a medical benefit. If that was indeed the case, Radient Technologies may well be a non-starter in its quest to get into the cannabis business.
No need to worry. Though it took weeks to get some much-needed clarification, the DEA has finally explained what it was saying two months ago. Indeed, the new ruling may actually help the medical marijuana — cannabis — along. DEA spokesman Russ Baer said in an e-mail to The Cannabist, “(The rule change) recognizes that there is a potential medical benefit to some of the cannabinoids.”
Some still worry the wording of the law essentially, even if unintentionally, puts cannabinoids (or CBD) under the purveyance of the DEA; it’s currently not. Even so, if nothing else the ruling has the government moving towards clarity, after acknowledging CBD — the healthy version of the cannabis, and not the one that gets you high — has medical value. The next step is clarifying ho
- [By Matthew Briar]
There’s an old business adage…. it’s not so much what you know, but who you know. If that’ s truly the case (and it is), then shareholders in Radient Technologies Inc (CVE:RTI) should be elated. The newest member of the Board of Directors that not already knows a lot of the right people, but has pretty much done all of things Radient would like to accomplish in the near future. That is, he was on the board for another ingredient and chemical company that was eventually acquired, but he also holds a masters degree in engineering. He can do it all, understanding the art and science of the business.
It’s yet another reason for RTI investors to be enthused.
Radient Technologies isn’t exactly a new company, but it’s relative notoriety is a fairly new phenomenon.
The organization, in simplest terms, has developed an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along.
Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which drives out the targeting ingredient or component much faster than more conventional extraction methods. In fact, the pressure-driven process outperforms the conventional extraction on pretty much every front. That is, the technique reduces the extraction time from hours to minutes, delivers a higher active ingredient purity, increases the recovery of actives from often scarce biomass, and uses much less solvent and energy than the more typical approach.
The technique can, and already has, created natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics.
Hot Medical Stocks To Watch Right Now: SPDR Blmbg Barclays Intl Trs Bd ETF (BWX)
- [By Todd Shriber, ETF Professor]
DWFI also holds the SPDR Barclays Emerging Markets Local Bond ETF (NYSE: EBND), SPDR Barclays International Treasury Bond ETF (NYSE: BWX) and the SPDR Barclays Intermediate Term Corporate Bond ETF (NYSE: ITR).
Hot Medical Stocks To Watch Right Now: Patni Computer Systems Limited(PTI)
- [By Lisa Levin]
Proteostasis Therapeutics Inc (NASDAQ: PTI) shares shot up 162 percent to $6.16 after the company disclosed 'positive' PTI-428 data with statistical significance.
- [By William Romov]
Before we show you our pick, here are the top 10 penny stocks to watch this week
Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%
FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free